Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pimecrolimus, yet another intriguing topical immunomodulator.

Virendra N Sehgal1, Manish Pahwa

  • 1Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Delhi, India. drsehgal@ndf.vsnl.net.in

The Journal of Dermatological Treatment
|June 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacology and Therapeutics of Collagen-Based Stimulator Drug and Drug Supplement: Delivery (Management) and Approaches (Strategies).

Skinmed·2023
Same author

Intramatricial platelet-rich plasma in nail disorders: Amending the methodological omissions and unethical commissions.

Dermatologic therapy·2020
Same author

Dermoscopy Update: Review of Its Extradiagnostic and Expanding Indications and Future Prospects.

Dermatology practical & conceptual·2019
Same author

Drugs, discovery, and dermatology: Renbök, research and repurposing.

Drug discovery today·2019
Same author

Erectile Dysfunction/Impotence: An Update of Drugs, Drug Delivery/Management, and Approaches or Strategies.

Skinmed·2019
Same author

An office-based evaluation of various itraconazole brands.

Journal of the American Academy of Dermatology·2019
Same journal

Active surveillance for basal cell carcinoma: experiences of patients and proxies.

The Journal of dermatological treatment·2026
Same journal

Severe cutaneous adverse reactions associated with systemic antibiotics in acne vulgaris: a systematic review.

The Journal of dermatological treatment·2026
Same journal

Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.

The Journal of dermatological treatment·2026
Same journal

JAK inhibitor-associated acne: a mechanistic paradox with important clinical implications.

The Journal of dermatological treatment·2026
Same journal

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a <i>post hoc</i> analysis of a phase-III trial.

The Journal of dermatological treatment·2026
Same journal

Predictors of optimal disease control in atopic dermatitis with abrocitinib: a real-world study.

The Journal of dermatological treatment·2026
See all related articles

Pimecrolimus is an immunomodulator approved for atopic dermatitis in patients over two years old. Its use is expanding to other inflammatory skin conditions when standard treatments are ineffective.

Area of Science:

  • Dermatology
  • Immunology

Background:

  • Pimecrolimus is a topical immunomodulator.
  • It is approved for atopic dermatitis in individuals over two years of age.

Purpose of the Study:

  • To review the extended indications for pimecrolimus.
  • To discuss its use in various inflammatory dermatoses.

Main Methods:

  • Literature review of pimecrolimus in inflammatory dermatoses.
  • Analysis of current treatment guidelines and clinical evidence.

Main Results:

  • Pimecrolimus shows potential in treating various inflammatory skin conditions.
  • Its efficacy is noted particularly when conventional therapies fail.

Conclusions:

Related Experiment Videos

  • Pimecrolimus is a viable alternative treatment for specific inflammatory dermatoses.
  • Consideration of pimecrolimus should be reserved for cases unresponsive to standard treatments.